Could a white blood cell booster help shrink breast tumors?

NCT ID NCT03571633

First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 20 times

Summary

This study looks at whether adding pegfilgrastim (a drug that increases white blood cells) to standard chemotherapy and trastuzumab can help eliminate more cancer cells before surgery in women with early-stage HER2-positive breast cancer. About 90 participants will receive either the standard treatment or the standard treatment plus pegfilgrastim. The main goal is to see if more tumors completely disappear with the added drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHRU Besançon

    Besançon, 25000, France

  • Centre Hospitalier Annecy Genevois

    Pringy, France

  • Centre Hospitalier Universitaire de Saint Etienne

    Saint-Etienne, France

  • Centre Leon Berard

    Lyon, France

  • Centre de Lutte contre le Cancer Jean Perrin

    Clermont-Ferrand, 63000, France

  • Clinique Charcot

    Sainte-Foy-lès-Lyon, France

  • Groupe Hospitalier Mutualiste de Grenoble

    Grenoble, 38000, France

  • Hopital Prive Jean Mermoz

    Lyon, France

  • Institut Sainte Catherine

    Avignon, France

Conditions

Explore the condition pages connected to this study.